Insider · CIK 0001397266

Fust Matthew K

Reports to the SEC for 9 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001397266

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	$40.29	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−5,925 sh	$85.00	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−22.8K sh	$85.00	−$1.94M	5,925
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	$52.67	−$545K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,092 sh	$83.09	−$174K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−9,730 sh	$49.13	−$478K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.5K sh	$64.68	−$1.13M	0
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+5,925 sh	—	—	28,761
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,730 sh	—	—	9,730
2026-06-09	ATRAAtara Biotherapeutics, Inc.A Award	Director	AAward	+12K sh	—	—	30,188
2026-05-27	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2026-05-14	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.1K sh	—	—	14,058
2026-05-14	RAREUltragenyx Pharmaceutical Inc.A Award	Director	AAward	+7,751 sh	—	—	33,696
2025-09-26	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director	SSale	−16K sh	$44.75	−$716K	22,836
2025-09-26	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	2,092
2025-09-26	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$1.91	+$19.1K	38,836
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,350
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+6,900 sh	—	—	28,836
2025-06-10	ATRAAtara Biotherapeutics, Inc.A Award	Director	AAward	+7,828 sh	—	—	18,188
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+85.6K sh	—	—	85,586
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+28.6K sh	—	—	28,571
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.8K sh	—	—	0
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−85.6K sh	—	—	0
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−28.6K sh	—	—	0
2025-05-28	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.8K sh	—	—	27,802
2025-05-15	RAREUltragenyx Pharmaceutical Inc.A Award	Director	AAward	+5,740 sh	—	—	25,945
2025-05-15	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.8K sh	—	—	10,787
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+85.6K sh	—	—	85,586
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.8K sh	—	—	27,802
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+28.6K sh	—	—	28,571
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−85.6K sh	—	—	0
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.8K sh	—	—	0
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−28.6K sh	—	—	0
2024-10-18	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,844 sh	—	—	85,586
2024-10-18	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,205 sh	—	—	0
2024-10-18	NMRANeumora Therapeutics, Inc.S Sale	Director	SSale	−14K sh	$17.03	−$239K	20,100
2024-10-18	NMRANeumora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,205 sh	$8.79	+$54.5K	26,305
2024-10-18	NMRANeumora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+7,844 sh	$2.52	+$19.8K	34,149
2024-10-17	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,156 sh	—	—	93,430
2024-10-17	NMRANeumora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,800 sh	$8.79	+$15.8K	25,683
2024-10-17	NMRANeumora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,156 sh	$2.52	+$5,433.12	27,839
2024-10-17	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,783 sh	—	—	0
2024-10-17	NMRANeumora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,783 sh	$8.32	+$31.5K	23,883
2024-10-17	NMRANeumora Therapeutics, Inc.S Sale	Director	SSale	−7,739 sh	$17.01	−$132K	20,100
2024-10-17	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,800 sh	—	—	6,205
2024-06-18	RAREUltragenyx Pharmaceutical Inc.A Award	Director	AAward	+5,345 sh	—	—	20,205
2024-06-18	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,900 sh	—	—	9,900
2024-06-13	NMRANeumora Therapeutics, Inc.A Award	Director	AAward	+20.1K sh	—	—	20,100
2024-06-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+28.6K sh	—	—	28,571

Recent filings

Accepted (ET)
Sep 14
Fust Matthew K0001628280-26-059902
SEC(opens sec.gov)
Jun 224
Fust Matthew K0001628280-26-044717
SEC(opens sec.gov)
Jun 114
Fust Matthew K0000905148-26-002920
SEC(opens sec.gov)
May 294
Fust Matthew K0001610717-26-000173
SEC(opens sec.gov)
May 184
Fust Matthew K0001397266-26-000002
SEC(opens sec.gov)
Sep 304
Fust Matthew K0001658247-25-000010
SEC(opens sec.gov)
Jun 134
Fust Matthew K0000950170-25-086266
SEC(opens sec.gov)
Jun 124
Fust Matthew K0000905148-25-002141
SEC(opens sec.gov)
May 304
Fust Matthew K0000950170-25-079925
SEC(opens sec.gov)

Companies

Address

C/O ELECTRA THERAPEUTICS, INC. 230 E GRAND AVENUE, SUITE S-100

SOUTH SAN FRANCISCO, CA, 94080